Cannabis use in Spanish patients with multiple sclerosis: Fulfilment of patients' expectations?

Journal of the Neurological Sciences

Volumn 273, Issue 1-2, 2008, Pages 103-107

  Martínez Rodríguez, Jose E ^a   Munteis, Elvira ^a   Carreño, Mar ^b   Blanco, Yolanda ^b   Roquer, Jaume ^a   Abanades, Sergio ^c   Graus, Francesc ^b   Saiz, Albert ^b  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

Cannabis; Multiple sclerosis; Pain; Quality of life; Spasticity

Indexed keywords

CANNABIS;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG CONTROL; DRUG DEPENDENCE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT SATISFACTION; PREVALENCE; PRIORITY JOURNAL; RECREATION; RISK FACTOR; SPAIN; STRUCTURED QUESTIONNAIRE; SYMPTOMATOLOGY;

EID: 50049131049     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2008.06.037     Document Type: Article

References (15)

1. Zajicek J., Fox P., Sanders H., Wright D., Vickery A., Nunn J., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362 (2003) 1517-1526
2. Rog D.J., Nurmikko T.J., Friede T., and Young C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65 (2005) 812-819
3. Collin C., Davies P., Mutiboko I.K., and Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 14 (2007) 290-296
4. Killestein J., Hoogervorst E.L., Reif M., Kalkers N.F., Van Loenen A.C., Staats P.G., et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58 (2002) 1404-1407
5. Chong M.S., Wolff K., Wise K., Tanton C., Winstock A., and Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler 12 (2006) 646-651
6. Bufill E., Blesa R., Galan I., and Dean G. Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. J Neurol Neurosurg Psychiatry 58 (1995) 577-581
7. Wade D.T., Makela P.M., House H., Bateman C., and Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12 (2006) 639-645
8. Clark A.J., Ware M.A., Yazer E., Murray T.J., and Lynch M.E. Patterns of cannabis use among patients with multiple sclerosis. Neurology 62 (2004) 2098-2100
9. Consroe P., Musty R., Rein J., Tillery W., and Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38 (1997) 44-48
10. Gorter R.W., Butorac M., Cobian E.P., and van der Sluis W. Medical use of cannabis in the Netherlands. Neurology 64 (2005) 917-919
11. Page S.A., Verhoef M.J., Stebbins R.A., Metz L.M., and Levy J.C. Cannabis use as described by people with multiple sclerosis. Can J Neurol Sci 30 (2003) 201-205
12. Ware M.A., Adams H., and Guy G.W. The medical use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 59 (2005) 291-295
13. Arévalo-Martin A., Vela J.M., Molina-Holgado E., Borrell J., and Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 23 (2003) 2511-2516
14. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404 (2000) 84-87
15. Zajicek J.P., Sanders H.P., Wright D.E., Vickery P.J., Ingram W.M., Reilly S.M., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76 (2005) 1664-1669